MOG (35-55): Gold-Standard Peptide for Multiple Sclerosis Animal Models

Executive Summary: MOG (35-55) is a synthetic peptide corresponding to residues 35–55 of human myelin oligodendrocyte glycoprotein, widely used to induce experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) research (APExBIO). It triggers robust T and B cell immune responses, leading to demyelination and neuroinflammation in susceptible mouse strains (Xu et al., 2025). The peptide is highly soluble in water and DMSO but insoluble in ethanol, requiring specific preparation protocols for reproducibility. Benchmark studies show dose-dependent induction of EAE, with clear molecular correlates in oxidative stress and matrix remodeling pathways. Recent research highlights the importance of regulatory mechanisms such as PARP7-mediated STAT1/STAT2 degradation in modulating disease severity (Xu et al., 2025).

Biological Rationale

MOG (35-55) is derived from human myelin oligodendrocyte glycoprotein, a central nervous system antigen in the immunoglobulin superfamily. It represents a key epitope recognized by autoreactive T cells in both human MS and animal EAE models. The peptide is a critical tool for dissecting autoimmune mechanisms and testing therapeutic interventions in neuroinflammation and demyelinating disease (Flag-Tag Protein Article, extending its mechanistic focus by integrating in vivo benchmarks here). MOG (35-55) allows researchers to model the relapsing-remitting disease course characteristic of human MS, including immune cell infiltration and myelin loss.

Mechanism of Action of MOG (35-55)

Upon administration with complete Freund's adjuvant (CFA), MOG (35-55) initiates a cascade of immune events. It is processed and presented by antigen-presenting cells, activating CD4+ T cells specific for the 35–55 epitope. This leads to clonal expansion, cytokine release, and recruitment of B cells, resulting in the production of anti-MOG autoantibodies. The ensuing immune response causes demyelination, axonal injury, and neuroinflammation. In vitro, MOG (35-55) decreases total protein concentration while increasing NADPH oxidase and matrix metalloproteinase-9 (MMP-9) activities, linking it to oxidative stress and extracellular matrix remodeling (Xu et al., 2025). Recent advances clarify how IFN-I signaling, specifically through STAT1/STAT2 regulation by PARP7, modulates disease expression in the EAE model (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) consistently induces EAE in C57BL/6 and HLA-DR2 transgenic mice when administered subcutaneously at 50–150 μg doses with CFA, recapitulating MS-like pathology (Xu et al., 2025).
• Peptide solubility is ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO; insoluble in ethanol (APExBIO product data: A8306).
• Stock solutions at 0.5 mg/mL in sterile water, with warming and ultrasonic bath, ensure reproducibility (APExBIO protocol).
• MOG (35-55) triggers rapid T and B cell activation, and anti-MOG antibody production, leading to demyelinating lesions and weight loss in mice (Mouse Genotype Article; this article updates with new signaling insights).
• PARP7 inhibition restores STAT1/STAT2 levels and reduces EAE severity, highlighting the pathway's translational relevance (Xu et al., 2025).

Applications, Limits & Misconceptions

MOG (35-55) is the benchmark for reproducible induction of EAE and is widely cited in preclinical MS research. It enables the study of neuroinflammation, immune cell trafficking, and therapeutic efficacy of candidate drugs. The peptide is also useful for dissecting molecular pathways such as oxidative stress and IFN-I signaling. However, its effectiveness and the disease phenotype may vary by mouse strain, adjuvant, and dosing regimen. For a comprehensive perspective on scenario-driven troubleshooting in EAE modeling, see Scenario-Driven Solutions; this article provides mechanistic updates and workflow integration parameters.

Common Pitfalls or Misconceptions

• MOG (35-55) does not induce EAE in all mouse strains: Susceptibility is strain-dependent; for example, BALB/c mice are typically resistant (Xu et al., 2025).
• Incorrect solvent choice leads to precipitation: The peptide is insoluble in ethanol and must be dissolved in water or DMSO (APExBIO).
• Storage errors cause degradation: Stock solutions should be desiccated and stored at –20°C; repeated freeze-thaw cycles reduce activity (APExBIO).
• Not a direct model of all MS subtypes: EAE primarily models relapsing-remitting MS and may not recapitulate primary progressive forms.
• Overreliance on clinical scores: Neurological scoring must be complemented with histological and molecular endpoints for accurate disease assessment.

Workflow Integration & Parameters

For experimental use, dissolve MOG (35-55) (SKU: A8306) at 0.5 mg/mL in sterile water, warm gently, and sonicate if needed (product protocol). Prepare fresh or store desiccated at –20°C. Typical dosing is 50–150 μg per mouse, administered subcutaneously with complete Freund's adjuvant. Pertussis toxin is often co-administered to enhance disease induction. Disease progression is monitored by daily weight and neurological scoring. For mechanistic studies, analyze T/B cell activation, anti-MOG antibody titers, and markers of oxidative stress such as NADPH oxidase and MMP-9 activity (MHC Class II Antigen Article; this article delineates stepwise integration and highlights the impact of IFN-I regulation).

Conclusion & Outlook

MOG (35-55) remains the gold-standard peptide for inducing EAE and modeling MS-like disease in preclinical research. It enables reproducible studies of neuroinflammation, immune regulation, and therapeutic intervention. New insights into IFN-I pathway modulation, such as PARP7 inhibition and STAT1/STAT2 stabilization, are refining the utility and translational value of this model (Xu et al., 2025). APExBIO’s MOG (35-55) (A8306) sets the benchmark for consistency and workflow reproducibility in autoimmune encephalomyelitis research. Ongoing integration with molecular and imaging readouts will further advance multiple sclerosis research.